Pharmaceuticals company Zydus Lifesciences announced Q2FY26 results Revenue from operations at Rs 61,232 million, up 17% over last year. Research & Development (R&D;) investments for the quarter stood at Rs 4,820 million (7.9% of revenues). EBITDA for the quarter was Rs 20,158 million, up 38% YoY. EBITDA margin for the quarter stood at 32.9%, which is an improvementof 500 bps on a YoY basis. Net Profit for the quarter was Rs 12,586 million, up 38% YoY. Capex (organic) for the quarter was Rs 4,911 million. Sharvil Patel, Managing Director, Zydus Lifesciences, said: Our strong performance this quarter reaffirms the power of our diversified business model and our execution capabilities across geographies and verticals. We delivered robust revenue growth and industry-leading profitability, aided by consistent outperformance in our US and India formulations businesses, sustained high growth in International Markets as well as strategic acquisitions in Wellness and MedTech. These results reflect our commitment to sustainable growth and global expansion, anchored in quality, compliance, and patient-centric innovation. Result PDF